Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456500 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL4507384 | 0.79 | CA2 (0.42) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL22379887 | 0.75 | CYP1A2 (0.46) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL7519025 | 0.73 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL28781609 | 0.72 | HDAC1 (0.35) | ALDH1A1CA2MAPTCYP3A4CA1 | |
| SCHEMBL2788792 | 0.72 | GLRA3 (0.65) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL13082627 | 0.70 | XDH (0.50) | ALDH1A1CA2POLBCYP1A2HIF1A | |
| SCHEMBL27750044 | 0.70 | CA2 (0.48) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL13083065 | 0.69 | ERN1 (0.33) | MAPTCYP3A4 | |
| SCHEMBL311508 | 0.69 | GABRA1 (0.47) | SMN1; SMN2ALDH1A1CA2POLBTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097388-B1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7915299-B2 | 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100249161-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100249161-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100249161-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100063122-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMlDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-11 | — | — | US | disclosed |
| EP-2097391-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | High Point Pharmaceuticals, LLC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2097388-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | High Point Pharmaceuticals, LLC (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008059026-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059024-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059024-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249161-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | GPR119, PGC, FABP4 | SMN1; SMN2 4537/4885ALDH1A1 687/4885CA2 812/4885 |
| US-20100063122-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMlDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | GPR119, HAGH, ALDH2 | SMN1; SMN2 4393/4885ALDH1A1 251/4885CA2 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.